
Keywords: اینترلوکین 23; UNITI Trials; Inflammatory Bowel Disease Treatment; IBD; Anti-IL12/23; 6-MP; 6-mercaptopurine; AUC; area under the curve; AZA; azathioprine; CD; Crohn's disease; CDAI; Crohn's Disease Activity Index; CRP; Creactive protein; ECLIA; electrochemilumines